The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - AstraZeneca; Sysmex
 
Yuichiro Tsukada
No Relationships to Disclose
 
Koji Inamori
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Shiseido; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; Daiichi Sankyo; Eisai; Incyte; IQvia; Mediscience Planning; Merck Sharp & Dohme; NanoCarrier; Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Shigenori Homma
No Relationships to Disclose
 
Mamoru Uemura
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Asahi Kasei; Bayer; Chugai Pharma; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Daisuke Kotani
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Takeda
Consulting or Advisory Role - Merck Serono
 
Shota Fukuoka
Research Funding - Bayer (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Naoki Nakamura
No Relationships to Disclose
 
Makoto Fukui
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma; Johnson & Johnson
 
Motohiro Kojima
No Relationships to Disclose
 
Yosuke Togashi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices; Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Astellas Pharma; AstraZeneca; Becton Dickinson; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Debiopharm Group; KYOWA HAKKO BIO; Kyowa Hakko Kirin; Merck Serono; Oncolys BioPharma; Ono Pharmaceutical; Pfizer; SRL Diagnostics; Sumitomo Group; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Masaaki Ito
Stock and Other Ownership Interests - A-Traction
Honoraria - Applied Medical; Chugai Pharma; Covidien/Medtronic; Johnson & Johnson; Olympus; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - EBM Co.; Muranaka Medical Instruments Co.
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)